Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
Autor: | Andrew Ertel, Leighann Litcher-Kelly, Sushil Allen Luis, Antonio Abbate, David Cella, Matt Magestro, David Lin, Brittany Klooster, Fang Fang, A. Beutler, Allan L. Klein, Martin M. LeWinter, Paul Cremer, John F. Paolini |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
Time Factors Health-related quality of life Anti-Inflammatory Agents Phases of clinical research Pilot Projects 030204 cardiovascular system & hematology 0302 clinical medicine Quality of life Adrenal Cortex Hormones Recurrence Pericarditis 030212 general & internal medicine Qualitative Research education.field_of_study Middle Aged Rilonacept C-Reactive Protein Mental Health Treatment Outcome Female Recurrent pericarditis Cardiology and Cardiovascular Medicine Research Article medicine.drug Adult medicine.medical_specialty Adolescent Recombinant Fusion Proteins Population Interviews as Topic Young Adult 03 medical and health sciences Internal medicine Patient experience medicine Humans Diseases of the circulatory (Cardiovascular) system Patient Reported Outcome Measures education Aged Angiology Drug Tapering business.industry Discontinuation Functional Status RC666-701 Concomitant Quality of Life Interleukin-1 cytokine trap business Biomarkers |
Zdroj: | BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-14 (2021) BMC Cardiovascular Disorders |
ISSN: | 1471-2261 |
Popis: | Background Impact of recurrent pericarditis (RP) on patient health-related quality of life (HRQoL) was evaluated through qualitative patient interviews and as an exploratory endpoint in a Phase 2 trial evaluating the efficacy and safety of rilonacept (IL-1α/IL-1β cytokine trap) to treat RP. Methods Qualitative interviews were conducted with ten adults with RP to understand symptoms and HRQoL impacts, and the 10-item Patient-Reported Outcomes Measurement Information System Global Health (PROMIS GH) v1.2 was evaluated to determine questionnaire coverage of patient experience. The Phase 2 trial enrolled participants with active symptomatic RP (A-RP, n = 16) and corticosteroid-dependent participants with no active recurrence at baseline (CSD-RP, n = 9). All participants received rilonacept weekly during a 6-week base treatment period (TP) plus an optional 18-week extension period (EP). Tapering of concomitant medications, including corticosteroids (CS), was permitted during EP. HRQoL was assessed using the PROMIS GH, and patient-reported pain and blood levels of c-reactive protein (CRP) were collected at Baseline and follow-up periods. A secondary, descriptive analysis of the Phase 2 trial efficacy results was completed using HRQoL measures to characterize both the impact of RP and the treatment effect of rilonacept. Results Information from qualitative interviews demonstrated that PROMIS GH concepts are relevant to adults with RP. From the Phase 2 trial, both participant groups showed impacted HRQoL at Baseline (mean PROMIS Global Physical Health [GPH] and Global Mental Health [GMH], were lower than population norm average). In A-RP, GPH/MPH improved by end of base TP and were sustained through EP (similar trends were observed for pain and CRP). Similarly, in CSD-RP, GPH/MPH improved by end of TP and further improved during EP, during CS tapering or discontinuation, without disease recurrence (low pain scores and CRP levels continued during the TP and EP). Conclusion This is the first study demonstrating impaired HRQoL in RP. Rilonacept treatment was associated with HRQoL improvements using PROMIS GH scores. Maintained/improved HRQoL during tapering/withdrawal of CS without recurrence suggests that rilonacept may provide an alternative to CS. Trial registration: ClinicalTrials.Gov; NCT03980522; 5 June 2019, retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT03980522. |
Databáze: | OpenAIRE |
Externí odkaz: |